Skip to main
SGHT
SGHT logo

Sight Sciences (SGHT) Stock Forecast & Price Target

Sight Sciences (SGHT) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Sight Sciences Inc. is positioned for positive growth, driven by anticipated increases in revenue due to accelerated market share gains in Minimally Invasive Glaucoma Surgery (MIGS) and enhanced adoption of the TearCare System. The company's commitment to its Surgical Glaucoma business, which is expected to align with overall market growth trends, provides a solid foundation for sustaining revenue streams. Furthermore, improvements in earnings per share forecasts for 2025 and 2026 reflect an optimistic outlook, illustrating the company's progress towards achieving profitability while maintaining projected revenues of $75 million and $82 million in those years.

Bears say

Sight Sciences Inc. has reiterated its 2025 revenue guidance at $72-76 million, while anticipating a mid-single-digit percentage decline in year-over-year revenue for the Surgical Glaucoma segment in the third quarter of 2025. The company faces several challenges, including increasing competition in the minimally invasive glaucoma surgery (MIGS) market, slow progress in securing insurance coverage for its TearCare system, and ongoing issues with cash burn. Additionally, management has adjusted its 2025 operating expense guidance down to $95-99 million from $101-105 million, despite projecting $12 million in annualized savings from workforce reductions, indicating concerns about financial stability.

Sight Sciences (SGHT) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sight Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sight Sciences (SGHT) Forecast

Analysts have given Sight Sciences (SGHT) a Buy based on their latest research and market trends.

According to 6 analysts, Sight Sciences (SGHT) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sight Sciences (SGHT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.